# Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II Study

> **NCT04872582** · PHASE2 · UNKNOWN · sponsor: **XIANG YANQUN** · enrollment: 33 (actual)

## Conditions studied

- Metastatic Nasopharyngeal Carcinoma
- Chemotherapy Effect

## Interventions

- **DRUG:** PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab

## Key facts

- **NCT ID:** NCT04872582
- **Lead sponsor:** XIANG YANQUN
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-29
- **Primary completion:** 2023-01-04
- **Final completion:** 2024-10
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2023-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04872582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04872582, "Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II Study". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04872582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*